Navigation Links
Prometheus Signs Research & Collaboration Agreement with Leading Worldwide Pharmaceutical Company
Date:2/7/2012

SAN DIEGO, Feb. 7, 2012 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the execution of a research and collaboration agreement with an unnamed leading worldwide pharmaceutical company. The collaboration will use Prometheus' proprietary oncology diagnostic platform (CEER) to develop diagnostic arrays relating to the partner's oncology pipeline.  The CEER arrays may ultimately be used in clinical trials for patient selection and may potentially accelerate the development of novel oncology therapeutic products.

Under the terms of the non-exclusive agreement, Prometheus will receive an upfront payment for the development of the first diagnostic array, additional payments for the development of each additional array, and research and development support and testing fees.

"This program represents an important addition to the expanding list of collaborations using our proprietary CEER diagnostic platform," said Joseph M. Limber, President and Chief Executive Officer of Prometheus. "We believe our technology can increase the probability of success in clinical trials and constitutes a significant step towards personalized medicine in cancer treatment, with the ultimate goal of improving the potential outcome for patients."

Prometheus' proprietary oncology diagnostic platform has the ability to measure the expression and activation of specific cancer pathways with high levels of sensitivity and specificity via tissue or blood sample. This technology has the potential to be used not only in the development process to select and evaluate the efficacy of drugs but also in the clinical setting to enable real-time molecular profiling, monitor drug effectiveness and direct the use of a growing number of targeted therapies.

About Prometheus

Prometheus Laboratories Inc. is committed to improving lives through the development and commercialization of novel pharmaceutical and diagnostic products that enable physicians to provide greater individualized patient care. Prometheus is a leader in applying the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and is applying these principles to oncology. Its strategy includes the marketing and delivery of pharmaceutical products complemented by proprietary diagnostic testing services. By integrating therapeutics and diagnostics, Prometheus believes it can provide physicians with more targeted solutions to optimize care for their patients. Prometheus became part of Nestle Health Science in July 2011.  Prometheus' corporate offices are located in San Diego, California. For more information about Prometheus, please visit www.prometheuslabs.com.

About Nestle Health Science

Nestle Health Science, a fully-owned subsidiary of Nestle S.A., has been operational since January 1, 2011 and has worldwide headquarters in Lutry, Switzerland. Nestle Health Science offers nutritional solutions for people with specific dietary needs related to illnesses, disease states or the special challenges of different life stages. For more information about Nestle Health Science, please visit www.nestlehealthscience.com.


'/>"/>
SOURCE Prometheus Laboratories Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Prometheus Presents Findings From Development of PROMETHEUS(R) IBS Diagnostic, First Blood Test for IBS, at ACG Annual Scientific Meeting
2. Prometheus and Rosetta Genomics Announce License and Collaboration Agreement
3. Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW
4. Prometheus Launches ProOnc Dx Cancer Diagnostics
5. Prometheus Acquires Exclusive Rights to PROLEUKIN(R) (aldesleukin) in the U.S.
6. Prometheus Announces New Method for Real-Time Monitoring of Patients Treated With Biologic Therapy
7. Prometheus and Bayer HealthCare Enter into Services Agreement to Conduct Mutational Analysis
8. Prometheus Highlights Record Performance in 2010
9. Prometheus Obtains Exclusive US Commercialization Rights for RENCAREX®
10. Prometheus Announces Agreement to be Acquired by Nestle Health Science
11. Prometheus and the Medco Research Institute® to Evaluate the Use of Prometheus Thiopurine Metabolite Testing for Optimizing Treatment of Inflammatory Bowel Disease Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2017)... Viverae ® , a leader in workplace ... IBM ® Watson Campaign Automation, implementing behavioral messaging ... a personalized experience. Through digital engagement, the platform prompts ... real time. The enhanced experience drives engagement by focusing ... they are in their journey to health. ...
(Date:4/18/2017)... , April 18, 2017  Astute Medical, Inc., developer ... series to be presented at the 2017 National Kidney ... today and continues through April 22. Physicians will present ... used to assess risk for acute kidney injury (AKI) ... failure (ADHF). Elevated levels of TIMP-2 ...
(Date:4/18/2017)... 18, 2017  Socionext Inc. and SOINN Inc. ... 2016, in which Socionext extracts and delivers biometrics ... achieved initial results in reading ultrasound images from ... SOINN. The results will be introduced at Medtec ... at booths 4505 & 4507. In ...
Breaking Medicine Technology:
(Date:4/27/2017)... ... April 27, 2017 , ... Healthcare companies are trying to meet ... reject an outdated healthcare executive resume. , “If you’re a healthcare executive open to ... and wondering if it’s as ready as you are for a new job search. ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... exhibitor sponsorship at MobileIron Live! 2017 in Santa Clara, California. Each ... immersive, educational approach to helping organizations maximize the benefits of mobility in their ...
(Date:4/27/2017)... ... April 27, 2017 , ... Plastic Surgery Associates is excited to ... to present at the upcoming Aesthetic Meeting. Held in San Diego, at the San ... and Canales will lend their expertise to the Premier Global Hot Topics session, speaking ...
(Date:4/26/2017)... ... April 26, 2017 , ... The ... Awards recipients, comprised of organizations and individuals who have stretched the boundaries ... 2017 President’s Awards recognize individuals and organizations on the forefront of healthcare ...
(Date:4/26/2017)... , ... April 26, 2017 , ... ... distinction of Customer Excellence upon National Registry of Emergency Medical Technicians ... drives Financial Performance,” said Dr. Jan G. West, Ph.D. , CEO & ...
Breaking Medicine News(10 mins):